Johnson & Johnson $JNJ Shares Purchased by Security National Bank of Sioux City Iowa IA

Security National Bank of Sioux City Iowa IA boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 27.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,143 shares of the company’s stock after buying an additional 3,878 shares during the quarter. Johnson & Johnson makes up 1.9% of Security National Bank of Sioux City Iowa IA’s holdings, making the stock its 12th biggest position. Security National Bank of Sioux City Iowa IA’s holdings in Johnson & Johnson were worth $4,608,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blueline Advisors LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $25,000. Outlook Capital Management LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $28,000. MidAtlantic Capital Management Inc. purchased a new position in Johnson & Johnson during the fourth quarter valued at $37,000. Matrix Trust Co grew its position in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the period. Finally, Hyposwiss Advisors SA purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $42,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson remains attractive to income-focused investors as a Dividend Aristocrat with 64 consecutive years of dividend increases. Analysts also point to its defensive characteristics, healthy balance sheet, buyback potential and ability to provide steady cash returns amid economic and inflation uncertainty. 3 Strong Buy Dividend Aristocrat Stocks to Generate Steady Cash
• Positive Sentiment: Recent drug launches, pipeline progress and oncology data are supporting the growth case. Management has highlighted underlying growth despite the loss of Stelara sales, with revenue reportedly rising 5.6% after excluding a significant Stelara-related drag. J&J Up 18% in Three Months
• Neutral Sentiment: Reports that J&J may sell its DePuy Synthes orthopedic unit for approximately $20 billion have renewed focus on portfolio strategy and capital allocation. A transaction could unlock value or fund growth, but the sale remains only potential and could reduce the company’s MedTech scale. J&J Faces a Fresh Valuation Test on DePuy Sale Talk
• Neutral Sentiment: CEO Joaquin Duato’s appointment to PepsiCo’s independent board, effective December 1, adds visibility to J&J’s leadership but is not a direct change to J&J’s earnings outlook. PepsiCo Welcomes Joaquin Duato to Its Board
• Negative Sentiment: Investors remain concerned about Stelara’s patent loss, MedTech weakness and billions of dollars in talc-related litigation liabilities. In addition, J&J’s elevated valuation after its strong run may limit upside unless operating results continue to exceed expectations. Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Johnson Rice reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Guggenheim lifted their price target on Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Scotiabank reissued an “outperform” rating and issued a $305.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a report on Monday, August 3rd. Finally, Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $274.13.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 0.1%

Shares of JNJ stock traded down $0.25 on Friday, hitting $269.97. 16,409,193 shares of the stock traded hands, compared to its average volume of 8,077,023. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. Johnson & Johnson has a twelve month low of $173.33 and a twelve month high of $281.07. The firm’s 50-day moving average price is $263.49 and its two-hundred day moving average price is $246.55. The stock has a market capitalization of $650.61 billion, a PE ratio of 31.28, a PEG ratio of 2.55 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson’s quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.